Jessica S. Donington, MD of NYU Langone Health talks about the IASLC Lung Cancer Staging Project and why some factors are not included. Whats coming next and what arent certain other factors in play? There are a lot of factors like number of lymph nodes involved rather than lymph node location. Looking into things like lymphovascular invasion, lymphoro evasion, why they werent able to made it in the staging system?
With the staging system and how it worked, it doesn’t only work for patients who have been resected and have pathological staging, but it also has to worked in clinical staging. There are lots of things learned from resected specimen, which impacts prognosis, but cant be put into the staging right now.